Bn Immunotherapeutics, Inc.

Bavarian Nordic A/s

Fatema Legrand

Alain Delcayre

Reiner Laus

Stefanie Mandl

Ryan Blair Rountree

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Use of MVA to treat prostate cancer

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Growing community of inventors

San Carlos, CA, United States of America

Fatema Legrand